Phase 1/2 trial of XPO1 inhibitor selinexor plus docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer.
von Itzstein MS, Burns TF, Dowell JE, Horn L, Camidge DR, York SJ, Eaton KD, Kyle K, Fattah FJ, Liu J, Mu-Mosley H, Gupta A, Nadeem U, Gao A, Zhang S, Gerber DE.
von Itzstein MS, et al. Among authors: york sj.
Clin Cancer Res. 2024 Dec 9. doi: 10.1158/1078-0432.CCR-24-1722. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 39651955